Sep 2026· Expert Review of Clinical Immunology· Vol 22, pp. 989 - 1001· 0 citations· 89 references
Medicine
TL;DR
The tools reviewed are promising adjuncts for differential diagnosis, endotyping, response prediction and monitoring, but few are standardized or prospectively validated; priorities for validation and equitable clinical integration are outlined.
Abstract
ABSTRACT Introduction Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and is clinically and biologically heterogeneous. Its diagnosis remains clinical, supported by validated criteria, with no single confirmatory test, yet the expansion of targeted systemic therapies has intensified the need for objective tools to support diagnosis and stratify patients. Areas covered This review summarizes the established clinical framework of AD diagnosis and the emerging tools intended to complement it: circulating and skin-derived biomarkers, minimally invasive tape stripping, the skin microbiome, instrumental barrier assessment, noninvasive biofluids, advanced optical imaging (reflectance confocal microscopy, optical coherence tomography and line-field confocal OCT) and artificial-intelligence and digital tools, with attention to special populations. The discussion is informed by a multi-database search (PubMed, Embase, Cochrane Library and Web of Science) to 2026. Expert opinion Clinical diagnosis remains the reference standard, and the experienced clinician still outperforms any single test. The tools reviewed are promising adjuncts for differential diagnosis, endotyping, response prediction and monitoring, but few are standardized or prospectively validated; priorities for validation and equitable clinical integration are outlined.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in high-income countries and is characterized by marked clinical heterogeneity and a relapsing course. Despite its high prevalence, the diagnosis of AD remains largely clinical and is often challenging due to overlapping features with other inf...
I. Dermitzakis, E. Sotiriou, Ioanna Vakirli et al.· Dermatology Practical &...· 0 citations
Atopic dermatitis (AD) is a chronic, relapsing, and remitting condition that affects approximately 10% of the population. It is a multifactorial disease involving immune dysregulation, gene mutations, and environmental factors that ultimately disrupt skin barrier restoration, causing pruritic lesions. Given the marked...
Stephanie Sawicki, Anjali Dhawan, Dikshya Devkota et al.· International Journal of Mol...· 0 citations
BACKGROUND
Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by immune dysregulation, epidermal barrier dysfunction, microbiome imbalance, pruritus, and xerosis. Despite therapeutic advances, topical treatments remain the foundation of AD management across all severities. However, most existing topi...
Peter A. Lio, Latanya Benjamin, Mercedes E. Gonzalez et al.· Journal of Drugs in Dermatol...· 0 citations
Background/Objectives: Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus caused by an abnormal type 2 (Th2) immune response. It is a leading cause of dysphagia in both pediatric and adult populations. Endoscopy with biopsy remains the standard approach for diagnosis, but its invasive nature and need...
Maanasa Pulavarty, Amy Meehan, Cary M. Qualia· Diagnostics· 0 citations
BACKGROUND
Atopic dermatitis (AD) is a chronic, fluctuating inflammatory skin disease in which severity assessment relies on subjective clinical scoring. However, these approaches do not capture subclinical inflammation that may precede disease worsening or follow disease resolution. Furthermore, comprehensive research...
Rob Byers, P. Andrew, Sura Sahib et al.· British Journal of Dermatolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.